Page last updated: 2024-12-08

2-methoxystypandrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Methoxystypandrone: was isolated from a Chinese herb Polygonum cuspidatum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PolygonumgenusA plant genus of the family POLYGONACEAE that is an ingredient of Shou-Wu-Pian, a Chinese herbal preparation (DRUGS, CHINESE HERBAL). The common name of black bindweed also refers to TAMUS or Fallopia (use POLYGONACEAE).[MeSH]PolygonaceaeThe only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH]

Cross-References

ID SourceID
PubMed CID158739
CHEMBL ID322776
CHEBI ID169725
MeSH IDM0415508

Synonyms (19)

Synonym
85122-21-0
6-acetyl-5-hydroxy-2-methoxy-7-methylnaphthalene-1,4-dione
CHEBI:169725
6-acetyl-5-hydroxy-2-methoxy-7-methyl-2,3-dihydro-[1,4]naphthoquinone
6-acetyl-5-hydroxy-2-methoxy-7-methyl-naphthalene-1,4-dione
2-methoxystypandrone
CHEMBL322776 ,
bdbm50107000
6-acetyl-5-hydroxy-2-methoxy-7-methyl-[1,4]naphthoquinone
1,4-naphthalenedione, 6-acetyl-5-hydroxy-2-methoxy-7-methyl-
DTXSID10234258
AKOS028108639
6-acetyl-5-hydroxy-2-methoxy-7-methyl-1,4-dihydronaphthalene-1,4-dione
2-methoxy-6-acethyl-7-methyljuglone
6-acetyl-5-hydroxy-2-methoxy-7-methyl-1,4-naphthoquinone
FS-9099
2-methoxy-6-acetyl-7-methyljuglone
CS-0017414
HY-N1738
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthoquinoneA polycyclic aromatic ketone metabolite of naphthalene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PapainCarica papaya (papaya)IC50 (µMol)23.00000.00201.504510.0000AID155386
Genome polyprotein Human rhinovirus sp.IC50 (µMol)4.60000.00052.98388.2000AID163631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID155386Inhibitory activity against papain using HPLC assay2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
AID163631Inhibitory activity against HRV 3Cpro using HPLC assay2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's7 (58.33)24.3611
2020's4 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]